Bioteque (4107) Q3 2025 earnings summary

Executive summary

• Operating revenue for the nine months ended September 30, 2025 was NT$1,568,283 thousand, nearly flat compared to NT$1,568,328 thousand in the same period last year.

• Net income for the nine months was NT$383,633 thousand, down from NT$394,033 thousand year-over-year.

• Basic earnings per share for the nine months was NT$5.54, compared to NT$5.69 in the prior year.

• Comprehensive income for the nine months was NT$340,902 thousand, reflecting a negative impact from foreign exchange differences.

Financial highlights

• Gross margin for the nine months was 44%, consistent with the prior year.

• Operating income for the nine months was NT$489,944 thousand, slightly up from NT$480,157 thousand year-over-year.

• Cash and cash equivalents at September 30, 2025 were NT$1,000,476 thousand, down from NT$1,319,102 thousand a year earlier.

• Total assets at September 30, 2025 were NT$4,491,896 thousand, nearly unchanged from NT$4,492,159 thousand at September 30, 2024.

• Cash dividends of NT$5.00 per share were distributed in 2025, up from NT$4.50 per share in 2024.

Outlook and guidance

• Management expects no significant impact from new IFRS standards effective in 2026 and 2027.

• The Group is evaluating the impact of IFRS 18, to be adopted in Taiwan in 2028.